585 results match your criteria Cutaneous CD30+ Ki-1 Anaplastic Large-Cell Lymphoma


Primary Cutaneous CD30+ Lymphoproliferative Disorders: a Comprehensive Review.

Curr Hematol Malig Rep 2020 May 20. Epub 2020 May 20.

City of Hope National Medical Center, 1500 E. Duarte Road, Duarte, CA, 91010, USA.

Purpose Of Review: Primary cutaneous CD30+ T-cell lymphoproliferative disorders (CD30+ LPDs) are the second most common cutaneous lymphomas after mycosis fungoides and Sezary syndrome. They include primary cutaneous anaplastic large cell lymphoma (pcALCL), lymphomatoid papulosis (LyP), and borderline lesions. The purpose of this literature review is to consolidate the available evidence on the primary cutaneous CD30+ LPD in order to define the tools for correct diagnosis and appropriate treatment. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11899-020-00583-4DOI Listing

The importance of differentiating between Mycosis Fungoides with CD30 positive large cell transformation and Mycosis Fungoides with co-existent primary cutaneous Anaplastic Large Cell Lymphoma.

J Am Acad Dermatol 2020 Apr 22. Epub 2020 Apr 22.

Department of Clinical Haematology, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, Australia; Faculty of Medicine, Nursing, and Health Sciences, Monash University, Clayton, Australia. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jaad.2020.04.073DOI Listing

Breast Implant-associated Anaplastic Large Cell Lymphoma: Review and Multiparametric Imaging Paradigms.

Radiographics 2020 May-Jun;40(3):609-628. Epub 2020 Apr 17.

From the Departments of Radiology (B.S., E.P.), Hematopathology (A.D.A., A.C.W.), Oncology (C.B.), and Hematology (S.S., S.I., D.E.S.), Royal Marsden Hospital, Fulham Road, London SW3 6JJ, England; Department of Medical Oncology, Royal Marsden Hospital Chelsea, London, England (A.J.R.); and University of Exeter Medical School, Exeter, England (R.S.).

Breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) is a new provisional category in the 2016 World Health Organization (WHO) classification of lymphoid neoplasms, and its incidence is rising owing to increasing recognition of this complication of breast implant insertion. At a median of 10 years after implant insertion, the typical presenting features are sudden-onset breast swelling secondary to peri-implant effusion and less frequently mass-forming disease. Histologic features comprise pleomorphic cells expressing CD30 and negative anaplastic lymphoma kinase (ALK) receptor, similar to systemic and cutaneous ALK-negative anaplastic large cell lymphoma (ALCL). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1148/rg.2020190198DOI Listing
April 2020
2.602 Impact Factor

Combined Modality Treatment With Brentuximab Vedotin and Radiation Therapy for Primary Cutaneous Anaplastic Large Cell Lymphoma: A Case Report.

J Hematol 2019 Sep 30;8(3):132-136. Epub 2019 Sep 30.

Department of Medicine, Division of Medical Oncology and Hematology, Mayo Clinic Health System, 1221 Whipple St., Eau Claire, WI, 54703, USA.

Primary cutaneous anaplastic large cell lymphoma (pcALCL) is a rare form of non-Hodgkins lymphoma. Current frontline treatments for pcALCL include surgical resection, anthracycline-based chemotherapy, and/or radiation therapy (RT) depending on disease severity. While brentuximab vedotin (BV) has been used for refractory/relapsed cases, it recently received Food and Drug Administration (FDA) approval for use in combination with chemotherapy for peripheral T-cell lymphomas. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.14740/jh534DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7153663PMC
September 2019

Primary Cutaneous CD30+ Anaplastic Large T Cell Lymphoma in a Patient Treated with Cyclosporine for Actinic Reticuloid.

Case Rep Dermatol Med 2020 25;2020:9435242. Epub 2020 Mar 25.

Skin Cancer Center, Department of Dermatology, Ruhr-University Bochum, Bochum, Germany.

Actinic reticuloid (AR)-a subtype of chronic actinic dermatitis-clinically and histopathologically shows lymphoma-like features. We report a male patient initially diagnosed with erythrodermic cutaneous T cell lymphoma (CTCL) who developed severe broadband photosensitivity. Clinical evaluation, histopathology, and phototesting were consistent with AR. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2020/9435242DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7132347PMC

Brentuximab Vedotin for Treating Relapsed or Refractory CD30-Positive Cutaneous T-Cell Lymphoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.

Pharmacoecon Open 2020 Mar 23. Epub 2020 Mar 23.

Faculty of Health and Life Sciences, University of Liverpool, Thompson Yates Building, Liverpool, L69 3GB, UK.

As part of the single technology appraisal process, the National Institute for Health and Care Excellence invited Takeda UK Ltd to submit clinical- and cost-effectiveness evidence for brentuximab vedotin (BV) for treating relapsed or refractory CD30-positive (CD30+) cutaneous T-cell lymphoma (CTCL). The Liverpool Reviews and Implementation Group at the University of Liverpool was commissioned to act as the evidence review group (ERG). This article summarises the ERG's review of the company's submission for BV and the appraisal committee (AC) decision. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s41669-020-00203-0DOI Listing

Evidence linking atopy and staphylococcal superantigens to the pathogenesis of lymphomatoid papulosis, a recurrent CD30+ cutaneous lymphoproliferative disorder.

PLoS One 2020 12;15(2):e0228751. Epub 2020 Feb 12.

Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, United States of America.

Background: Primary cutaneous CD30+ lymphoproliferative disorders (CD30CLPD) are the second most common type of cutaneous T cell lymphoma (CTCL) and include lymphomatoid papulosis (LyP) and primary cutaneous anaplastic large cell lymphoma (pcALCL). Case reports and small patient series suggest an association of CD30CLPD with atopic disorders. However, the prevalence of atopy in patients with CD30CLPD in retrospective studies depends on patients' recall which is not always reliable. Read More

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0228751PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7015403PMC

Molluscum contagiosum infection with features of primary cutaneous anaplastic large cell lymphoma.

Dermatol Online J 2019 Nov 15;25(11). Epub 2019 Nov 15.

Department of Dermatology and Cutaneous Biology, Thomas Jefferson University, Philadelphia, PA.

CD30+ T cell pseudolymphomas (CD30+ PSL) are a group of benign inflammatory cutaneous disorders that can develop in settings of viral infections or drug reactions. Owing to their histological similarities to malignant lymphomas, these benign infiltrates are occasionally misdiagnosed as malignant, causing significant concerns for patients and physicians. Herein, we report a patient with CD30+ PSL associated with molluscum contagiosum whose initial biopsy revealed atypical large CD30-expressing cells, leading to a misdiagnosis of primary cutaneous anaplastic large cell lymphoma and referral to our cutaneous lymphoma clinic. Read More

View Article

Download full-text PDF

Source
November 2019

Brentuximab Vedotin in the Treatment of Peripheral T Cell Lymphoma and Cutaneous T Cell Lymphoma.

Curr Hematol Malig Rep 2020 Feb;15(1):9-19

Division of Oncology, Department of Medicine, Washington University School of Medicine, 660 S. Euclid, Box 8056, St. Louis, MO, 63110, USA.

Purpose Of Review: The recent development of brentuximab vedotin (BV), an antibody-drug conjugate targeting CD30-positive cells, has led to therapeutic advances in the treatment of T cell lymphomas. In this review, we discuss key studies of BV in peripheral T cell lymphoma (PTCL) and cutaneous T cell lymphoma (CTCL) and highlight important questions for further investigation.

Recent Findings: Monotherapy with BV has proven to be effective and well tolerated in patients with relapsed/refractory (R/R) CD30-positive CTCL. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11899-020-00561-wDOI Listing
February 2020

Primary Cutaneous Anaplastic Large Cell Lymphoma (pcALCL) in the Elderly and the Importance of Sport Activity Training.

Int J Environ Res Public Health 2020 01 29;17(3). Epub 2020 Jan 29.

Department of Mental Health and Preventive, University of Campania Luigi Vanvitelli, 80131 Naples, Italy.

Primary cutaneous anaplastic large cell lymphoma (pcALCL) is part of a spectrum of cutaneous CD30+ lymphoproliferative disease that also includes lymphomatoid papulosis. It often occurs in elderly patients, presenting at a median age of 60 years, although it may occur at any age. It is a CD30+ T-cell neoplasm composed of large cells with anaplastic, pleomorphic, or immunoblastic morphology, with exclusively cutaneous onset and localization. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/ijerph17030839DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7037068PMC
January 2020

Low-dose Methotrexate Treatment for Solitary or Localized Primary Cutaneous Anaplastic Large Cell Lymphoma: A Long-term Follow-up Study.

Acta Derm Venereol 2020 02 29;100(4):adv00069. Epub 2020 Feb 29.

Department of Dermatology, Kosin University College of Medicine, 49267 Busan, Korea.

Although low-dose methotrexate (MTX) has been used widely in treatment of a variety of dermatological diseases, including multifocal primary cutaneous anaplastic large cell lymphoma (PCALCL), it has not been established for use in the treatment guidelines for solitary or localized PCALCL. Furthermore, there has been no report of long-term follow-up data in Asian patients with PCALCL treated with low-dose MTX. To investigate the effectiveness and clinical outcome of treatment with low-dose MTX, clinical and long-term follow-up data of 7 patients with solitary or localized PCALCL were analysed retrospectively. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2340/00015555-3413DOI Listing
February 2020

Radiotherapy of primary cutaneous anaplastic large cell lymphoma: our experience in 30 cases.

Int J Dermatol 2020 Apr 9;59(4):469-473. Epub 2020 Jan 9.

UO Dermatologia, Università degli Studi di Milano, Milano, Italy.

Background: Since the observation of new cases of primary cutaneous anaplastic large cell lymphoma (PCALCL) with a seemingly aggressive clinical presentation and a favorable response to radiation therapy (RT), a review of our series has been performed to evaluate the results of RT.

Materials And Methods: The study is a retrospective analysis of 30 patients with PCALCL treated with conventional energy RT.

Results: About 55 fields of irradiation were performed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ijd.14754DOI Listing

ALCL by any other name: the many facets of anaplastic large cell lymphoma.

Pathology 2020 Jan 6;52(1):100-110. Epub 2019 Nov 6.

Department of Pathology, Yale New Haven Hospital, Yale University School of Medicine, New Haven, CT, United States. Electronic address:

Anaplastic large cell lymphomas (ALCLs) encompass a group of CD30(+) non-Hodgkin T-cell lymphomas. While the different subtypes of ALCLs may share overlapping clinical patient demographics as well as histological and immunohistochemical phenotypes, these tumours can drastically differ in clinical behaviour and genetic profiles. Currently, four distinct ALCL entities are recognised in the 2016 WHO classification: anaplastic lymphoma kinase (ALK)(+), ALK(-), primary cutaneous and breast implant-associated. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.pathol.2019.09.007DOI Listing
January 2020

Primary Cutaneous Anaplastic Large-Cell Lymphoma.

Dermatopathology (Basel) 2019 Apr-Jun;6(2):163-169. Epub 2019 Jun 26.

Nelson R Mandela School of Medicine, Department of Dermatology, University of KwaZulu-Natal, Durban, South Africa.

A 35-year-old male presented with a 6-month history of asymptomatic, generalised, self-healing lesions. On clinical examination, there were diffuse, ulcerated, necrotic papules and nodules with lymphoedema of the face. Histology sections confirmed atypical lymphoid-type cells which appeared round-to-oval with irregular nuclei (horseshoe-shaped). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000500259DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6827451PMC
June 2019
4 Reads

Clinicopathologic and microenvironmental analysis of primary cutaneous CD30-positive lymphoproliferative disorders: a 26 year experience from an academic medical center in Brazil.

Diagn Pathol 2019 Oct 22;14(1):115. Epub 2019 Oct 22.

Department of Pathology, Stanford University School of Medicine, Stanford, CA, 94305, USA.

Background: Primary cutaneous CD30+ lymphoproliferative disorders (pc-CD30-LPD) are a group of clonal T cell lymphoproliferative disorders that despite very similar tumor histology follow different and characteristic clinical courses, suggesting a homeostatic role of the tumor microenvironment. Little is known about tumor microenvironment and there is almost no literature about PD-L1 expression in pc-CD30-LPD.

Methods: This retrospective study presents a fully clinicopathologically characterized series of pc-CD30-LPDs from an academic medical center in Brazil, including 8 lymphomatoid papulomatosis (LyP), 9 primary cutaneous anaplastic large cell lymphoma (pcALCL) and 4 borderline lesions. Read More

View Article

Download full-text PDF

Source
https://diagnosticpathology.biomedcentral.com/articles/10.11
Publisher Site
http://dx.doi.org/10.1186/s13000-019-0900-7DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6805531PMC
October 2019
5 Reads

CD30 Cross-Reactivity and Expression in Feline Normal Tissues and Lymphomas.

Vet Pathol 2020 Jan 22;57(1):49-55. Epub 2019 Oct 22.

Department of Histopathology, Istituto Zooprofilattico Sperimentale delle Venezie, Legnaro, Italy.

CD30 is a transmembrane glycoprotein of the tumor necrosis factor receptor superfamily included in the diagnostic algorithm of human cutaneous, anaplastic large cell and Hodgkin lymphomas and represents an optimal therapeutic target for CD30 tumors. Similar diagnostic and therapeutic approaches are largely missing for feline lymphomas. Cross-reactivity of the antihuman CD30 receptor clone Ber-H2 was investigated in feline lymphomas. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/0300985819875745DOI Listing
January 2020
1 Read

Does Breast Implant-Associated ALCL Begin as a Lymphoproliferative Disorder?

Plast Reconstr Surg 2020 01;145(1):30e-38e

Providence, R.I.; Dallas, Texas; New York, N.Y.; and Rome, Italy From the Department of Dermatology, Boston University School of Medicine and Roger Williams Medical Center; the Department of Plastic Surgery, University of Texas Southwestern Medical School; the Department of Pathology and Laboratory Medicine, Weill Cornell College of Medicine; and the Department of Clinical and Molecular Medicine, Sapienza University, Pathology Unit, Sant'Andrea Hospital.

Breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) has been included as a provisional entity in the revised version of the World Health Organization Classification of Tumors of Haematopoietic and Lymphoid Tissue. To increase opportunities to intervene with early diagnosis, treatment, and possible prevention, it is important to consider that BIA-ALCL may evolve from a preexisting lymphoproliferative disorder characterized by (1) an indolent localized (in situ) disease in approximately 80 percent of reported cases; (2) a requirement for external cytokine stimulation for cell survival; (3) CD30 cells in some clinically benign seromas/capsules; (4) undetected T-cell clonality in some cases; (5) JAK/STAT mutations in only a minority of cases; and (6) cure by capsulectomy and implant removal in most cases. BIA-ALCL resembles CD30 cutaneous lymphoproliferative disorder: ALK, CD30 anaplastic cells with an aberrant T-cell phenotype; overexpression of oncogenes (JUNB, SATB1, pSTAT3, SOCS3) in lymphomatoid papulosis; frequent apoptosis; complete spontaneous regression in lymphomatoid papulosis; and partial spontaneous regression in cutaneous ALCL. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/PRS.0000000000006390DOI Listing
January 2020
3 Reads

Lymphomatoid Papulosis Type B in a Patient with Crohn's Disease Treated with TNF-Alpha Inhibitors Infliximab and Adalimumab.

Acta Dermatovenerol Croat 2019 Sep;27(3):202-204

Márta Medvecz, MD, PhD, Department of Dermatology, Venerology and Dermatooncology, Semmelweis University, Mária utca 41, 1085 Budapest, Hungary;

Dear Editor, Lymphomatoid papulosis (LP) is a chronic, recurrent, usually self-limited papulonecrotic or papulonodular skin disease, which belongs to the group of primary cutaneous CD30+ lymphoproliferative disorders (1). Three main histological subtypes of LP have been recognized: type A (histiocytic), type B (mycosis fungoides-like), and type C (anaplastic large cell lymphoma-like). Recently, new histologic LP variants classified as type D (CD8-positive, cytotoxic form) and type E (angioinvasive form) have also been described. Read More

View Article

Download full-text PDF

Source
September 2019
7 Reads

Primary multifocal anaplastic large cell lymphoma with eyelid involvement: a case report.

Arq Bras Oftalmol 2019 12;82(6):514-516. Epub 2019 Sep 12.

Departamento de Cirugía, Facultad de Medicina, Universidad de Valencia, Valencia, Spain.

Ocular adnexal involvement in CD30+ lymphoproliferative disorders is rare. We report the case of a 73-year-old woman with a relapsing primary cutaneous anaplastic large cell lymphoma on her eyelid. A systemic extension study excluded extracutaneous involvement. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.5935/0004-2749.20190094DOI Listing
March 2020
2 Reads

Lymphomatoid Papulosis and Other Lymphoma-Like Diseases.

Dermatol Clin 2019 Oct 6;37(4):471-482. Epub 2019 Aug 6.

Department of Dermatology and Cutaneous Surgery, University of South Florida Morsani College of Medicine, 12901 Bruce B. Downs Boulevard, Tampa, FL 33612, USA. Electronic address:

Pityriasis lichenoides et varioliformis acuta and pityriasis lichenoides chronica are the 2 main subtypes of pityriasis lichenoides. They represent the acute and chronic forms of the disease; both may have clonal T cells. Several treatment modalities are used, but it has been difficult to determine efficacy because of the possibility of spontaneous remission. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.det.2019.05.005DOI Listing
October 2019
4 Reads

Variable loss of CD30 expression by immunohistochemistry in recurrent cutaneous CD30+ lymphoid neoplasms treated with brentuximab vedotin.

J Cutan Pathol 2019 Nov 2;46(11):823-829. Epub 2019 Aug 2.

Dermatopathology Unit, Department of Pathology, Massachusetts General Hospital, Boston, Massachusetts.

Aims: Brentuximab vedotin is a monoclonal anti-CD30 antibody-drug conjugate that has been used to treat a variety of CD30+ neoplasms. The phenomenon of antigen loss has been observed in patients treated with the anti-CD20 antibody rituximab. This study seeks to assess for antigen loss in the setting of recurrent CD30+ neoplasms treated with brentuximab vedotin. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/cup.13545DOI Listing
November 2019
9 Reads
1.560 Impact Factor

Challenges in the diagnosis of primary cutaneous CD30 anaplastic large-cell lymphoma.

Br J Dermatol 2020 Jan 9;182(1):233-234. Epub 2019 Sep 9.

Department of Dermatology, APHP, Saint-Louis Hospital, Paris, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjd.18328DOI Listing
January 2020
14 Reads

Sarcomatoid Variant of Primary Cutaneous Anaplastic Large Cell Lymphoma.

Am J Dermatopathol 2019 Dec;41(12):e164-e167

Department of Dermatology, Kurume University School of Medicine, Fukuoka, Japan.

Sarcomatoid variant of primary cutaneous anaplastic large cell lymphoma is rare and is a diagnostic challenge. Clinical manifestation often mimics that of an infectious disease. Predominance of spindle cells in the biopsy specimen prevents from suspecting lymphoma. Read More

View Article

Download full-text PDF

Source
http://Insights.ovid.com/crossref?an=00000372-900000000-9811
Publisher Site
http://dx.doi.org/10.1097/DAD.0000000000001483DOI Listing
December 2019
5 Reads

Treatment of primary cutaneous anaplastic large cell lymphoma.

Arch Craniofac Surg 2019 Jun 20;20(3):207-211. Epub 2019 Jun 20.

Department of Pathology, Dong-Kang General Hospital, Ulsan, Korea.

Primary cutaneous anaplastic large cell lymphoma (C-ALCL) is a rare subtype of primary cutaneous lymphoma with a favorable prognosis. Primary cutaneous CD30+ lymphoproliferative disorders, which include C-ALCL and lymphomatoid papulosis, are the second most common group of cutaneous T-cell lymphomas. C-ALCL is comprised of large cells with anaplastic, pleomorphic, or immunoblastic cytomorphology, and indeed, more than 75% of the tumor cells express the CD30 antigen. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.7181/acfs.2018.02201DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6615420PMC
June 2019
6 Reads

How I treat primary cutaneous CD30 lymphoproliferative disorders.

Blood 2019 08 4;134(6):515-524. Epub 2019 Jun 4.

Division of Hematology, Department of Medicine, University of Washington, Seattle, WA.

The primary cutaneous CD30 lymphoproliferative disorders are a family of extranodal lymphoid neoplasms that arise from mature postthymic T cells and localize to the skin. Current classification systems recognize lymphomatoid papulosis (LyP), primary cutaneous anaplastic large cell lymphoma, and borderline cases. In the majority of patients, the prognosis of primary cutaneous CD30 lymphoproliferative disorders is excellent; however, relapses are common, and complete cures are rare. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood.2019000785DOI Listing
August 2019
8 Reads

Conjugation of DM1 to anti-CD30 antibody has potential antitumor activity in CD30-positive hematological malignancies with lower systemic toxicity.

MAbs 2019 Aug/Sep;11(6):1149-1161. Epub 2019 Jun 4.

c Department of Technical Quality, Shanghai Jiaolian Drug Research and Development Co., Ltd , Shanghai , China.

An anti-CD30 antibody-drug conjugate incorporating the antimitotic agent DM1 and a stable SMCC linker, anti-CD30-MCC-DM1, was generated as a new antitumor drug candidate for CD30-positive hematological malignancies. Here, the and pharmacologic activities of anti-CD30-MCC-DM1 (also known as F0002-ADC) were evaluated and compared with ADCETRIS (brentuximab vedotin). Pharmacokinetics (PK) and the safety profiles in cynomolgus monkeys were assessed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/19420862.2019.1618674DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6748589PMC
January 2020
27 Reads

RF - Brentuximab as Treatment for CD30 Primary Cutaneous Lymphoma.

Actas Dermosifiliogr 2019 Nov 28;110(9):769-770. Epub 2019 May 28.

Servicio de Dermatología, Hospital Clínic de Barcelona, Universitat de Barcelona, Barcelona, España. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ad.2018.03.025DOI Listing
November 2019
8 Reads

Complete Resolution of Primary Cutaneous Anaplastic Large Cell Lymphoma With Topical Imiquimod

J Drugs Dermatol 2019 May;18(5):460-462

Primary cutaneous anaplastic large cell lymphoma (pc-ALCL) is a CD30+ subtype of cutaneous T-cell lymphoma. It typically has a very favorable prognosis; however, traditional treatment can be expensive, invasive, and associated with significant adverse events. Imiquimod is a topical toll-like receptor approved by the Food and Drug Administration (FDA) for genital warts, actinic keratosis, and primary superficial basal cell carcinoma. Read More

View Article

Download full-text PDF

Source
May 2019
23 Reads

Aggressive T-cell lymphomas: 2019 updates on diagnosis, risk stratification, and management.

Authors:
Jasmine M Zain

Am J Hematol 2019 08 11;94(8):929-946. Epub 2019 Jun 11.

Department of Hematology/Hematopoietic Cell Transplantation, City of Hope Medical Center, Duarte, California.

Introduction: Aggressive T-cell lymphomas continue to have a poor prognosis. There are over 27 different subtypes of peripheral T-cell lymphoma (PTCL) and we are now beginning to understand the differences between the various subtypes beyond histologic variations.

Molecular Pathogenesis Of Various Subtypes Of Ptcl: Gene expression profiling can help in diagnosis and prognostication of various subtypes including PTCL-nos and anaplastic large cell lymphoma. Read More

View Article

Download full-text PDF

Source
https://onlinelibrary.wiley.com/doi/abs/10.1002/ajh.25513
Publisher Site
http://dx.doi.org/10.1002/ajh.25513DOI Listing
August 2019
37 Reads

Linfoma anaplásico de células T grandes primario cutáneo CD30+. Serie de nueve casos.

Gac Med Mex 2019 ;155(2):130-135

Secretaría de Salud, Hospital General "Dr. Manuel Gea González", Departamento de Dermatología.

Introduction: CD30+ anaplastic large T cell lymphoma is a cutaneous primary lymphoma in which there is no evidence of systemic disease; histopathological study is required for its diagnosis.

Objective: To present the cases diagnosed with primary cutaneous CD30+ anaplastic large T-cell lymphoma over a 24-year period in Hospital General "Dr. Manuel Gea González" Department of Dermatology. Read More

View Article

Download full-text PDF

Source
http://gacetamedicademexico.com/frame_esp.php?id=265
Publisher Site
http://dx.doi.org/10.24875/GMM.18004656DOI Listing
November 2019
10 Reads

Expression of CCR3 and CCR4 Suggests a Poor Prognosis in Mycosis Fungoides and Sézary Syndrome.

Acta Derm Venereol 2019 Jul;99(9):809-812

Department of Dermatology, University of Tokyo Graduate School of Medicine, Tokyo, Japan.

Tumor cells in cutaneous T-cell lymphoma express limited numbers of chemokine receptors. We investigated the expression patterns of CXCR3, CCR3, CCR4 and CCR10 in mycosis fungoides, Sézary syndrome, lym-phomatoid papulosis and anaplastic large cell lymphoma in 121 skin biopsy samples. CXCR3 was expressed in 86% of mycosis fungoides cases but in no anaplastic large cell lymphoma cases. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2340/00015555-3207DOI Listing
July 2019
13 Reads

Systemic, primary cutaneous, and breast implant-associated ALK-negative anaplastic large-cell lymphomas present similar biologic features despite distinct clinical behavior.

Virchows Arch 2019 Aug 6;475(2):163-174. Epub 2019 Apr 6.

Département de Biopathologie Cellulaire et Tissulaire des Tumeurs, CHU Montpellier, Hôpital Gui De Chauliac, 34275, Montpellier, France.

Despite distinct clinical presentation and outcome, systemic, primary cutaneous, and breast implant-associated anaplastic large cell lymphomas (S-, PC-, BI-ALCL) ALK-negative (ALK-) show similar histopathological features including the presence of the "hallmark" cells with horseshoe-shaped nuclei and CD30 protein expression. The purpose was to better characterize these three entities using immunohistochemistry and FISH (Fluorescent in situ hybridization) to identify biomarkers differently expressed and that might be involved in their pathogenesis. Twenty-two S-ALCL ALK-, 13 PC-ALCL, and 2 BI-ALCL were included. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00428-019-02570-4DOI Listing
August 2019
22 Reads

Clear Cell Primary Cutaneous Anaplastic Large Cell Lymphoma.

Am J Dermatopathol 2019 Oct;41(10):e111-e115

Departments of Pathology, and.

A case of primary cutaneous anaplastic large cell lymphoma that was characterized by a striking clear cell appearance occurring in the thigh of a 38-year-old man is described. The tumor presented as a large ulcer with indurated borders and serosanguinous base measuring 9.0 × 4. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/DAD.0000000000001422DOI Listing
October 2019
29 Reads

Mycosis Fungoides Associated With Lesions in the Spectrum of Primary Cutaneous CD30+ Lymphoproliferative Disorders: The Same Process or 3 Coexisting Lymphomas?

Am J Dermatopathol 2019 Nov;41(11):846-850

Departments of Dermatology.

Mycosis fungoides (MF) is the most common type of cutaneous T-cell lymphoma, primary cutaneous CD30 lymphoproliferative disorders (pc CD30 LPD) being the second most prevalent. There is evidence that MF and pc CD30 LPD may coexist and share T-cell clonality, suggesting a common origin. These findings were supported by a T-cell receptor clonality assessment by the polymerase chain reaction coupled with capillary electrophoresis, although results produced by this method may be ambiguous. Read More

View Article

Download full-text PDF

Source
http://Insights.ovid.com/crossref?an=00000372-900000000-9816
Publisher Site
http://dx.doi.org/10.1097/DAD.0000000000001423DOI Listing
November 2019
24 Reads

Existing and Emerging Therapies for Cutaneous T-Cell Lymphoma.

J Cutan Med Surg 2019 May/Jun;23(3):319-327. Epub 2019 Apr 3.

1 Department of Dermatology and Skin Science, University of British Columbia, Vancouver, Canada.

Cutaneous T-cell lymphomas (CTCL) are a heterogeneous group of non-Hodgkin lymphomas characterized by an infiltration of malignant monoclonal T lymphocytes into the skin. Mycosis fungoides (MF), the most common subtype, and the rarer Sézary syndrome (SS), are considered the classical forms of CTCL, which, because of a varying presentation and lack of genetic and immunophenotypical markers, can often have a delayed diagnosis. With skin-directed topical treatment being the mainstay of therapy in the early stages, there is an absence of long-term curative therapies for advanced disease. Read More

View Article

Download full-text PDF

Source
http://journals.sagepub.com/doi/10.1177/1203475419840629
Publisher Site
http://dx.doi.org/10.1177/1203475419840629DOI Listing
December 2019
18 Reads

Challenges of driving CD30-directed CAR-T cells to the clinic.

BMC Cancer 2019 Mar 6;19(1):203. Epub 2019 Mar 6.

Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, 27599, USA.

Chimeric antigen receptor T (CAR-T) cells are a promising new treatment for patients with relapsed or refractory hematologic malignancies, including lymphoma. Given the success of CAR-T cells directed against CD19, new targets are being developed and tested, since not all lymphomas express CD19. CD30 is promising target as it is universally expressed in virtually all classical Hodgkin lymphomas, anaplastic large cell lymphomas, and in a proportion of other lymphoma types, including cutaneous T cell lymphomas and diffuse large B cell lymphomas. Read More

View Article

Download full-text PDF

Source
https://bmccancer.biomedcentral.com/articles/10.1186/s12885-
Publisher Site
http://dx.doi.org/10.1186/s12885-019-5415-9DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6404322PMC
March 2019
33 Reads

Genetics of Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL).

Aesthet Surg J 2019 01;39(Suppl_1):S14-S20

Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN.

Breast implant-associated anaplastic large cell lymphoma (BIA-ALCL), a newly included provisional entity in the 2016 revision of the World Health Organization classification, is a distinct form of CD30-positive T-cell non-Hodgkin lymphoma that arises in association with a breast implant after reconstructive or cosmetic surgery. In addition to its characteristic clinical presentation, recent studies using next-generation sequencing have revealed that BIA-ALCL has a unique pattern of genetic alterations. BIA-ALCL is consistently negative for ALCL-related gene rearrangements involving ALK, DUSP22, and TP63. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/asj/sjy311DOI Listing
January 2019
10 Reads

The spectrum of CD30+ T cell lymphoproliferative disorders in the skin.

Chin Clin Oncol 2019 Feb 9;8(1). Epub 2019 Jan 9.

Division of Hematologic Malignancies and Hematopoietic Stem Cell Transplantation, Department of Medical Oncology, Thomas Jefferson University, Philadelphia, PA, USA.

Primary cutaneous CD30+ T cell lymphoproliferative disorders (pcCD30+ T cell LPDs) are a spectrum of pre-malignant to frankly neoplastic lymphoproliferations that comprise lymphomatoid papulosis (LyP), primary cutaneous anaplastic large cell lymphoma (pcALCL), and borderline lesions. Although the atypical T cells that are the hallmark of these disorders share the expression of CD30, as the identifying marker, the clinical presentation, histological features and clinical course are vastly different. Furthermore, histopathologic features of pcCD30+ T cell LPDs may overlap with other cutaneous and systemic lymphomas. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/cco.2018.12.03DOI Listing
February 2019
15 Reads

Primary cutaneous CD8+ and CD30+ T-cell lymphoproliferative disorders: case reports and clinical implications.

Eur J Dermatol 2019 Feb;29(1):39-44

Department of Pathology, Cliniques Universitaires Saint Luc, Université Catholique de Louvain (UCL), Brussels.

Background: CD8+ CD30+ primary cutaneous T-cell lymphomas (PCTCL) are rare entities with overlapping pathological features and variable outcome.

Objectives: We sought to highlight the importance of correlation between pathological findings and clinical presentation for correct classification of the disease.

Materials & Methods: Two cases of CD8+ CD30+ PCTCL were investigated. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1684/ejd.2018.3493DOI Listing
February 2019
22 Reads

Acitretin combined with NB-UVB in the treatment of cutaneous CD30-positive anaplastic large cell lymphoma.

Dermatol Ther 2019 03 27;32(2):e12834. Epub 2019 Feb 27.

Department of Dermatology, The Affiliated Hospital of Jiangsu University, Zhenjiang, China.

Cutaneous CD30 lymphoproliferative disorders represent a spectrum of skin lymphatic reticular proliferative diseases, including lymphomatoid papulosis (LYP), primary cutaneous anaplastic large cell lymphoma (PC-ALCL), and borderline lesions between them. Although they all express CD30 as a phenotypic marker and share overlapping immunophenotypic features, they differ in clinical manifestations, pathological features, treatment, and prognosis. LYP is a kind of benign disease characterized by recurrent papules and nodules, and may spontaneously regress. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/dth.12834DOI Listing
March 2019
13 Reads

CD30-positive primary cutaneous lymphoproliferative disorders: molecular alterations and targeted therapies.

Haematologica 2019 02 10;104(2):226-235. Epub 2019 Jan 10.

Department of Pathology, Hospital Universitario Fundación Jiménez Díaz, Madrid.

Primary cutaneous CD30-positive T-cell lymphoproliferative disorders are the second most common subgroup of cutaneous T-cell lymphomas. They include two clinically different entities with some overlapping features and borderline cases: lymphomatoid papulosis and primary cutaneous anaplastic large cell lymphoma. Molecular studies of primary cutaneous anaplastic large cell lymphoma reveal an increasing level of heterogeneity that is associated with histological and immunophenotypic features of the cases and their response to specific therapies. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3324/haematol.2018.197152DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6355473PMC
February 2019
16 Reads

CD30-Positive Lymphoproliferative Disorders.

Cancer Treat Res 2019;176:249-268

Division of Dermatology, City of Hope National Medical Center, Duarte, CA, USA.

Primary cutaneous CD30-positive lymphoproliferative disorders (CD30+ LPD) encompass lymphomatoid papulosis (LyP), primary cutaneous anaplastic large cell lymphoma (pcALCL), and borderline lesions [1]. CD30+ LPD are the second most common cutaneous T-cell lymphomas (CTCL) after mycosis fungoides (MF) and represent approximately 25% of all CTCL cases [2]. Their common phenotypic hallmark is an expression of the CD30 antigen, a cytokine receptor belonging to the tumor necrosis factor (TNF) receptor superfamily. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/978-3-319-99716-2_12DOI Listing
July 2019
29 Reads

Brentuximab vedotin in T-cell lymphoma.

Expert Rev Hematol 2019 01 18;12(1):5-19. Epub 2018 Dec 18.

a Department of Haematology , Peter MacCallum Cancer Centre , Melbourne , Australia.

Introduction: Brentuximab vedotin is an antibody-drug conjugate, which combines a CD30 monoclonal antibody with the microtubule-disrupting agent monomethylauristatin E. The utility of brentuximab vedotin has been explored in a number of diseases, with a recent focus on T-cell lymphoma, particularly systemic anaplastic large-cell lymphoma (sALCL) and cutaneous T-cell lymphoma (CTCL), as well as other peripheral T-cell lymphoma (PTCL) histologies. Areas covered: This review surveys current data on the efficacy of brentuximab vedotin in T-cell lymphoma, as well as embedding it in a therapeutic context by reviewing potential competitor agents in the clinic. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/17474086.2019.1
Publisher Site
http://dx.doi.org/10.1080/17474086.2019.1558399DOI Listing
January 2019
45 Reads

CD30+ T-cell lymphoproliferative disorders.

Chin Clin Oncol 2019 Feb 11;8(1). Epub 2018 Oct 11.

Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA.

The term "CD30+ T-cell lymphoproliferative disorders" describes a group of diverse diseases of the skin, subcutaneous tissues and mucosa that range from lesions requiring clinical observation to those necessitating systemic cytotoxic chemotherapy. Careful consideration of both clinical and histopathologic presentation is needed for appropriate diagnosis and treatment. This review will present the current classification of these disorders and potential treatment paradigms. Read More

View Article

Download full-text PDF

Source
http://cco.amegroups.com/article/view/21776
Publisher Site
http://dx.doi.org/10.21037/cco.2018.09.06DOI Listing
February 2019
46 Reads

Antibody-Based Therapies for Cutaneous T-Cell Lymphoma.

Am J Clin Dermatol 2019 Feb;20(1):115-122

University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 1452, Houston, TX, 77030-4009, USA.

Cutaneous T-cell lymphomas (CTCLs) are a group of non-Hodgkin's lymphomas that present in the skin. In early-stage disease, the course is generally chronic and indolent; however, in advanced stages of disease, therapies rarely provide long-lasting responses, and the only potential curative therapy is allogeneic hematopoietic stem-cell transplantation. This has led to the search for novel targeted therapies to better treat more advanced stages of CTCLs that cannot be controlled by typical treatment regimens. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s40257-018-0402-5
Publisher Site
http://dx.doi.org/10.1007/s40257-018-0402-5DOI Listing
February 2019
39 Reads

Common origin of sequential cutaneous CD30+ lymphoproliferations with nodal involvement evidenced by genome-wide clonal evolution.

Histopathology 2019 Mar 31;74(4):654-662. Epub 2019 Jan 31.

Aix-Marseille University, Marseille, France.

Aims: This study sought to clarify the molecular pathways underlying the putative evolution from lymphomatoid papulosis (LyP) to cutaneous anaplastic large-cell lymphoma (c-ALCL) and lymph node invasion (LNI).

Methods And Results: We analysed nine sequential tumours from the same patient presenting with parallel evolution of LyP (n = 3) and c-ALCL (n = 1) with LNI (n = 1), combined with systemic diffuse large B-cell lymphoma (DLBCL) (n = 4). Clonality analysis showed a common clonal T-cell origin in the five CD30+ lesions, and a common clonal B-cell origin in the four DLBCL relapses. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/his.13783
Publisher Site
http://dx.doi.org/10.1111/his.13783DOI Listing
March 2019
28 Reads

Long-term Follow-up of a Case of Lymphomatoid Papulosis with a Benign Course.

Acta Dermatovenerol Croat 2018 Oct;26(3):264-266

Jaka Radoš, MD, University Hospital Centre Zagreb Department of Dermatology and Venereology School of Medicine University of Zagreb Šalata 4, 10000 Zagreb , Croatia;

Dear Editor,We present the case of a 40-year old male patient with lymphomatoid papulosis of a waxing and waning course on whom three biopsies were performed during a 14-year period with no change in histopathological or immunophenotypical characteristics. Lymphomatoid papulosis (LP) is a chronic, recurrent, self-healing papulonodular skin eruption with the histopathologic features of a cutaneous T-cell lymphoma but an often benign and indolent clinical course (1). It is designated as a primary, cutaneous, CD30+ lymphoproliferative disorder. Read More

View Article

Download full-text PDF

Source
October 2018
60 Reads